NCT05739136View on ClinicalTrials.gov

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

Active, not recruitingOBSERVATIONAL

Enrollment

530

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Pregnancy RelatedPregnancy ComplicationsPregnancy, High Risk

Interventions

DRUG

Relugolix + Estradiol + Norethindrone Acetate

Relugolix combination therapy (relugolix 40 mg; estradiol 1 mg; norethindrone 0.5 mg)

Trial Locations (1)

01752

SMPA, Marlborough

All Listed Sponsors

lead

Sumitomo Pharma Switzerland GmbH

INDUSTRY

NCT05739136 - MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy | Biotech Hunter | Biotech Hunter